277 related articles for article (PubMed ID: 33492309)
1. Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity.
Falck-Jones S; Vangeti S; Yu M; Falck-Jones R; Cagigi A; Badolati I; Österberg B; Lautenbach MJ; Åhlberg E; Lin A; Lepzien R; Szurgot I; Lenart K; Hellgren F; Maecker H; Sälde J; Albert J; Johansson N; Bell M; Loré K; Färnert A; Smed-Sörensen A
J Clin Invest; 2021 Mar; 131(6):. PubMed ID: 33492309
[TBL] [Abstract][Full Text] [Related]
2. Severe COVID-19 Is Characterized by an Impaired Type I Interferon Response and Elevated Levels of Arginase Producing Granulocytic Myeloid Derived Suppressor Cells.
Dean MJ; Ochoa JB; Sanchez-Pino MD; Zabaleta J; Garai J; Del Valle L; Wyczechowska D; Baiamonte LB; Philbrook P; Majumder R; Vander Heide RS; Dunkenberger L; Thylur RP; Nossaman B; Roberts WM; Chapple AG; Wu J; Hicks C; Collins J; Luke B; Johnson R; Koul HK; Rees CA; Morris CR; Garcia-Diaz J; Ochoa AC
Front Immunol; 2021; 12():695972. PubMed ID: 34341659
[TBL] [Abstract][Full Text] [Related]
3. Monocytic-Myeloid Derived Suppressor Cells Suppress T-Cell Responses in Recovered SARS CoV2-Infected Individuals.
Beliakova-Bethell N; Maruthai K; Xu R; Salvador LCM; Garg A
Front Immunol; 2022; 13():894543. PubMed ID: 35812392
[TBL] [Abstract][Full Text] [Related]
4. Myeloid-derived suppressor cells and T cell populations in children with Multisystem Inflammatory Syndrome.
Bline KE; Wilt AL; Alexander RN; Andrews AN; Mertz SE; Ye F; Steele LM; Wolfe AL; Mejias A; Ramilo O
Pediatr Res; 2024 Apr; 95(5):1288-1294. PubMed ID: 38042945
[TBL] [Abstract][Full Text] [Related]
5. Circulating myeloid-derived suppressor cells may be a useful biomarker in the follow-up of unvaccinated COVID-19 patients after hospitalization.
Jiménez-Cortegana C; Salamanca E; Palazón-Carrión N; Sánchez-Jiménez F; Pérez-Pérez A; Vilariño-García T; Fuentes S; Martín S; Jiménez M; Galván R; Rodríguez-Chacón C; Sánchez-Mora C; Moreno-Mellado E; Gutiérrez-Gutiérrez B; Álvarez N; Sosa A; Garnacho-Montero J; de la Cruz-Merino L; Rodríguez-Baño J; Sánchez-Margalet V
Front Immunol; 2023; 14():1266659. PubMed ID: 38035104
[TBL] [Abstract][Full Text] [Related]
6. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.
;
Cell; 2022 Mar; 185(5):916-938.e58. PubMed ID: 35216673
[TBL] [Abstract][Full Text] [Related]
7. The Functional Roles of MDSCs in Severe COVID-19 Pathogenesis.
Len JS; Koh CWT; Chan KR
Viruses; 2023 Dec; 16(1):. PubMed ID: 38257728
[TBL] [Abstract][Full Text] [Related]
8. Blood molecular markers associated with COVID-19 immunopathology and multi-organ damage.
Chen YM; Zheng Y; Yu Y; Wang Y; Huang Q; Qian F; Sun L; Song ZG; Chen Z; Feng J; An Y; Yang J; Su Z; Sun S; Dai F; Chen Q; Lu Q; Li P; Ling Y; Yang Z; Tang H; Shi L; Jin L; Holmes EC; Ding C; Zhu TY; Zhang YZ
EMBO J; 2020 Dec; 39(24):e105896. PubMed ID: 33140861
[TBL] [Abstract][Full Text] [Related]
9. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity.
Veglia F; Sanseviero E; Gabrilovich DI
Nat Rev Immunol; 2021 Aug; 21(8):485-498. PubMed ID: 33526920
[TBL] [Abstract][Full Text] [Related]
10. Myeloid cell dynamics correlating with clinical outcomes of severe COVID-19 in Japan.
Takano T; Matsumura T; Adachi Y; Terahara K; Moriyama S; Onodera T; Nishiyama A; Kawana-Tachikawa A; Miki S; Hosoya-Nakayama K; Nakamura-Hoshi M; Seki S; Tachikawa N; Yoshimura Y; Miyata N; Horiuchi H; Sasaki H; Miyazaki K; Kinoshita N; Sudo T; Akiyama Y; Sato R; Suzuki T; Matano T; Takahashi Y
Int Immunol; 2021 Mar; 33(4):241-247. PubMed ID: 33538817
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-derived suppressor cells (MDSC): When good intentions go awry.
Sanchez-Pino MD; Dean MJ; Ochoa AC
Cell Immunol; 2021 Apr; 362():104302. PubMed ID: 33592540
[TBL] [Abstract][Full Text] [Related]
12. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients.
Tan AT; Linster M; Tan CW; Le Bert N; Chia WN; Kunasegaran K; Zhuang Y; Tham CYL; Chia A; Smith GJD; Young B; Kalimuddin S; Low JGH; Lye D; Wang LF; Bertoletti A
Cell Rep; 2021 Feb; 34(6):108728. PubMed ID: 33516277
[TBL] [Abstract][Full Text] [Related]
13. Monocytes and Macrophages, Targets of Severe Acute Respiratory Syndrome Coronavirus 2: The Clue for Coronavirus Disease 2019 Immunoparalysis.
Boumaza A; Gay L; Mezouar S; Bestion E; Diallo AB; Michel M; Desnues B; Raoult D; La Scola B; Halfon P; Vitte J; Olive D; Mege JL
J Infect Dis; 2021 Aug; 224(3):395-406. PubMed ID: 33493287
[TBL] [Abstract][Full Text] [Related]
14. Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19.
Janssen NAF; Grondman I; de Nooijer AH; Boahen CK; Koeken VACM; Matzaraki V; Kumar V; He X; Kox M; Koenen HJPM; Smeets RL; Joosten I; Brüggemann RJM; Kouijzer IJE; van der Hoeven HG; Schouten JA; Frenzel T; Reijers MHE; Hoefsloot W; Dofferhoff ASM; van Apeldoorn MJ; Blaauw MJT; Veerman K; Maas C; Schoneveld AH; Hoefer IE; Derde LPG; van Deuren M; van der Meer JWM; van Crevel R; Giamarellos-Bourboulis EJ; Joosten LAB; van den Heuvel MM; Hoogerwerf J; de Mast Q; Pickkers P; Netea MG; van de Veerdonk FL
J Infect Dis; 2021 Apr; 223(8):1322-1333. PubMed ID: 33524124
[TBL] [Abstract][Full Text] [Related]
15. Persistent cellular immunity to SARS-CoV-2 infection.
Breton G; Mendoza P; Hägglöf T; Oliveira TY; Schaefer-Babajew D; Gaebler C; Turroja M; Hurley A; Caskey M; Nussenzweig MC
J Exp Med; 2021 Apr; 218(4):. PubMed ID: 33533915
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses.
Vibholm LK; Nielsen SSF; Pahus MH; Frattari GS; Olesen R; Andersen R; Monrad I; Andersen AHF; Thomsen MM; Konrad CV; Andersen SD; Højen JF; Gunst JD; Østergaard L; Søgaard OS; Schleimann MH; Tolstrup M
EBioMedicine; 2021 Feb; 64():103230. PubMed ID: 33530000
[TBL] [Abstract][Full Text] [Related]
17. The COVID-19 immune landscape is dynamically and reversibly correlated with disease severity.
Bolouri H; Speake C; Skibinski D; Long SA; Hocking AM; Campbell DJ; Hamerman JA; Malhotra U; Buckner JH;
J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33529167
[TBL] [Abstract][Full Text] [Related]
18. Characterizing the immune responses of those who survived or succumbed to COVID-19: Can immunological signatures predict outcome?
Sami R; Fathi F; Eskandari N; Ahmadi M; ArefNezhad R; Motedayyen H
Cytokine; 2021 Apr; 140():155439. PubMed ID: 33524886
[TBL] [Abstract][Full Text] [Related]
19. A distinct innate immune signature marks progression from mild to severe COVID-19.
Chevrier S; Zurbuchen Y; Cervia C; Adamo S; Raeber ME; de Souza N; Sivapatham S; Jacobs A; Bachli E; Rudiger A; Stüssi-Helbling M; Huber LC; Schaer DJ; Nilsson J; Boyman O; Bodenmiller B
Cell Rep Med; 2021 Jan; 2(1):100166. PubMed ID: 33521697
[TBL] [Abstract][Full Text] [Related]
20. The presentation of SARS-CoV-2 peptides by the common HLA-A
Szeto C; Chatzileontiadou DSM; Nguyen AT; Sloane H; Lobos CA; Jayasinghe D; Halim H; Smith C; Riboldi-Tunnicliffe A; Grant EJ; Gras S
iScience; 2021 Feb; 24(2):102096. PubMed ID: 33521593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
